Learn More
BACKGROUND Fibrosis is the most common side effect after anti-vascular epithelial growth factor (VEGF) therapy (intravitreal bevacizumab) for retinal or choroidal neovascularization. This study was to investigate the efficacy of bevacizumab on the expressions of fibrosis-related cytokines in human umbilical vein endothelial cells (HUVECs) in vitro. (More)
Two mouse immunoglobulin G1 monoclonal antibodies that bind to the trichothecene mycotoxin T-2 were prepared. These antibodies, designated 12C12 and 15H6, had affinities for T-2 of 3.5 X 10(6) and 5.8 X 10(7) liters/mol, respectively. A competitive inhibition enzyme immunoassay that employed these antibodies had a sensitivity for T-2 of 50 ng per assay.(More)
  • 1